The Auris Medical Holding Inc (NASDAQ: EARS) stock has been on the move this morning in premarket trading.
The stock has gone up by 10% in premarket trading after having already rallied by as much as 35% in the previous three trading sessions. In light of such gains, it might be a good idea for investors to keep an eye on the Auris stock. There has been no news about the clinical stage firm this morning but it could be worthwhile to take a look at development from last month.
Last month, Auris announced its financial results for the second half of 2020 and the numbers seemed to have excited investors at the time. The total operating expenses for that period was CHF 2.9 million, which was considerably lower than CHF 3.2 million that the company had recorded in the same metric in the prior-year period. Research and development expenses remained flat at CHF 2 million.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.